So the patient can in fact have his or her medication with food as long as the meal does not contain fat or oils (e.g., a cup of black coffee or toast with jam and no butter). Taking the medicines with food also helps ease the nausea that many patients feel when taking the medicines on an empty stomach. The effect of food on the absorption of INH is not clear: two studies have shown reduced absorption with food but one study showed no difference. There is a small effect of food on the absorption of PZA and of EMB that is probably not clinically important.It is possible to test urine for isoniazid and rifampicin levels to check for compliance. The interpretation of urine analysis is based on the fact that isoniazid has a longer half-life than rifampicin:
urine positive for isoniazid and rifampicin – patient probably fully compliant
urine positive for isoniazid only – patient has taken his medication in the last few days preceding the clinic appointment, but had not yet taken a dose that day. urine positive for rifampicin only – patient has omitted to take his medication the preceding few days, but did take it just before coming to clinic. urine negative for both isoniazid and rifampicin – patient has not taken either medicine for a number of daysIn countries where doctors are unable to compel patients to take their treatment (e.g., the UK), some say that urine testing only results in unhelpful confrontations with patients and does not help increase compliance.
In the United States it is estimated that children 5 years and younger are the most at risk, receiving 50% of the total exposure, followed by laboratory personnel and then pet store employees. Other groups at increased risk are people over 65 years old, immunocompromised individuals, and pregnant women.Symptoms of RBF include sudden high temperature fevers with rigors, vomiting, headaches, painful joints/arthritis. A red, bumpy rash develops in about 75% of subjects. Symptoms of RBF can develop between 3 days and 3 weeks after exposure. While symptoms differ between Streptobacillary and Spirillary RBF, both types exhibit an incubation period before symptoms manifest. Due to its symptoms, RBF is often misdiagnosed by clinicians, leading to lingering symptoms and worsening conditions in patients; left untreated the mortality rate (death rate) of RBF is 13%. Even when treated, RBF can lead to migratory polyarthralgia, persistent rash, and fatigue  which can persist for weeks to years after initial infection and treatment. See also
Pasteurellosis
List of cutaneous conditions
Zoonosis

References
Rat Bite Fever (RBF) | CDC

Further reading
"Rat-bite Fever (RBF)". Centers for Disease Control and Prevention. Retrieved 28 February 2014. Centers for Disease Control Prevention (CDC) (January 2005). "Fatal rat-bite fever—Florida and Washington, 2003". MMWR Morb. Mortal. Wkly. Rep. 53 (51): 1198–202. PMID 15635289. Rat-bite fever (MyOptumHealth.com)
Tandon, R; Lee, M; Curran, E; Demierre, MF; Sulis, CA (Dec 15, 2006). "A 26-year-old woman with a rash on her extremities". Clinical Infectious Diseases. 43 (12): 1585–6, 1616–7. doi:10.1086/509574. PMID 17109293. Centers for Disease Control, (CDC) (Jun 8, 1984). "Rat-bite fever in a college student--California". MMWR.